AstraZeneca announces top-line results from EUCLID trial ahead of the AHA. Ticagrelor is no better than clopidogrel in patients who have peripheral artery disease, a large new study will show. On Tuesday morning AstraZeneca announced the top line results of the EUCLID (Examining Use of Ticagrelor in PAD) trial. The full results will be presented…
Ticagrelor No Better Than Clopidogrel In Peripheral Artery Disease
October 4, 2016 by Leave a Comment
ACE Inhibitor Improves Walking In People with Peripheral Artery Disease
February 5, 2013 by Leave a Comment
Giving an ACE inhibitor to people with peripheral artery disease (PAD) and intermittent claudication reduces pain and increases walking time, according to a new study published in JAMA. Currently the pharmacologic options for this patient population are few and have limited efficacy. Researchers at three Australian hospitals randomized 212 patients with PAD to receive the ACE…
FDA Approves Zilver PTX Drug-Eluting Stent For Peripheral Arterial Disease
November 15, 2012 by 1 Comment
The FDA today approved Cook Medical’s Zilver PTX stent. It is the first drug-eluting stent (DES) approved for the treatment of peripheral arterial disease (PAD) in the superficial femoral and proximal (i.e., above the knee) popliteal artery. The new stent will provide a new treatment option for treating patients with PAD. Current treatments include exercise,…
AHA Scientific Statement Spotlights Peripheral Artery Disease in Women
February 15, 2012 by Leave a Comment
Although peripheral artery disease (PAD) raises the risk of heart disease and stroke, it often goes undiagnosed and untreated, especially in women, according to a scientific statement issued by the American Heart Association and published in Circulation. Here are a few highlights of the statement: Although women develop PAD later than men, the total number…
Recent Comments